Teva Pharmaceutical Industries Limited (TEVA) Earnings

Teva Pharmaceutical Industries Limited is expected to report next earnings on July 29, 2026 (in NaN days), with a consensus EPS estimate of $0.53. TEVA has beaten EPS estimates in 10 of its last 12 reported quarters (average surprise +18.3% over the last four).

Next earnings
Jul 29, 2026in NaN days
EPS est $0.53 · Revenue est $4.1B
Track record
Beat EPS in 10 of 12 quarters
Avg surprise +18.3% (last 4 quarters)
Earnings history
Report dateEPS estEPS actualSurpriseRevenueRev. surprise
Apr 29, 2026$0.50$0.53+6.0%$4.0B+5.1%
Jan 28, 2026$0.65$0.96+47.7%$4.7B+21.7%
Nov 5, 2025$0.68$0.78+14.7%$4.5B+0.6%
Jul 30, 2025$0.63$0.66+4.8%$4.2B-4.3%
Jan 29, 2025$0.69$0.71+2.9%$4.2B+3.0%
Jul 31, 2024$0.57$0.61+7.0%$4.2B+1.6%
Jan 31, 2024$0.75$1.00+33.3%$4.5B+10.7%
Nov 8, 2023$0.60$0.60+0.0%$3.9B+3.1%
Aug 2, 2023$0.54$0.56+3.7%$3.9B+4.4%
Feb 8, 2023$0.68$0.71+4.4%$3.9B-0.1%
Nov 3, 2022$0.61$0.59-3.3%$3.6B-6.4%
Jul 26, 2022$0.57$0.68+19.3%$3.8B+0.3%

Source: company filings + earnings calendar. For informational purposes only — not investment advice.

Earnings call summary

Q1 FY2026 · April 29, 2026

AI summary of management’s prepared remarks and analyst Q&A. For informational purposes only — not investment advice.

Management highlights

• Pivot to growth strategy launched 3 years ago with 4 pillars: deliver growth engines, step up innovations, sustain generics powerhouse, focus business. • Acquisition of Amilex Bioscience for Ecopipan, a first-in-class asset for Tourette syndrome. • Q1 results driven by innovative portfolio strength. • Pipeline has 7 milestone readouts this year, including dubiketric maintenance data, anti-IL-15 vitiligo data in Q2, and various data in H2. • Generics business performing as planned with biosimilar portfolio driving growth in US. • R&D highlights include EU submission for Olanzapine LAI, completion of enrollment in DARI phase three program, positive maintenance data for Duva-Ketog, and progress on anti-IL-15 and MROSOMIN programs.

Guidance

• Reiterated 2027 financial targets: revenue mid-single digit, non-GAAP operating income 30%, net debt EBITDA less than 2, cash to earnings 80%. • MLX acquisition expected to be accretive to NAND gap EPS starting in 2028. • 2026 outlook: reaffirmed underlying financial metrics range, expected operating expenses towards higher end of 27-28% of revenue range, non-GAAP gross margin in 54.5%-55.5% range, free cash flow guidance range $2B-$2.4B remains unchanged. • Board instructed management to plan for share repurchase program subject to legal requirements.

Segment performance

Revenue was $4 billion, down 1% year-over-year. Adjusted EBITDA was $1.1 billion, up 2%. Non-GAAP EPS was $0.53%, up 2%. Free cash flow was $200 million, up 76%. Net debt to EBITDA was 2.42. Innovative portfolio grew 41%. Esteto grew 41% to $578 million. Yasedi grew 62% to $63 million. JV grew 35% to $196 million. Generics revenue was down 13% excluding Japan and generic Revlimid. Biosimilar portfolio is emerging with 11 products on market, 4 more to cover $16B originator sales by 2027, and 9 more to cover $58B by then.

Risks & headwinds

• Forward-looking statements involve risks and uncertainties due to factors described in earnings press release, 10Q, and 10K. • Geopolitical situation in Middle East monitored, but operations remain uninterrupted with no material impact on 2026 guidance as of now.

Analyst Q&A

  • Q: Louise Chen asked about Amilex acquisition synergies with CNS franchise and peak sales potential.

    A: Ecopipan has significant unmet medical need in pediatric Tourette's. Synergies in patient services, managed markets, etc. Peak sales potential based on unmet need.

  • Q: Glenn Santangelo asked about reconciling innovative portfolio growth and 2027 low single-digit growth expectation.

    A: Timing and impact of IRA on Esteto, need to see more quarters for other growth drivers.

  • Q: Matt Delatorre asked about capital allocation and branded pipeline.

    A: Free cash flow strong, plan to allocate for BD, share repurchases, debt pay down. Duva-Keto has potential across indications.

  • Q: Dennis Ding asked about Amilex transaction adult population and pricing.

    A: Ecopipan is pediatric treatment, pricing within orphan/rare range.

  • Q: Jason Gerbery asked about generics pipeline and IL-15 regulatory path.

    A: Can't comment on generic pipeline. IL-15 accelerated path due to execution confidence.

  • Q: Uma Rafat asked about MLX patent and FDA feedback.

    A: Ecobipam expected orphan drug exclusivity, FDA feedback positive on study data.

  • Q: David Amselem asked about MLX REMS and M&A strategy.

    A: No REMS expected for MLX. M&A strategy: neuroscience inorganically, immunology organically.

  • Q: Chris Schott asked about MLX ramp and Esteto quarterly dynamics.

    A: No peak sales guidance, Esteto destocking impact on Q2-Q3.

  • Q: Ash Verma asked about 700M BD payout and Middle East geopolitics.

    A: No impact on investor-grade debt timeline. Middle East impact minimal.

  • Q: Les Salewski asked about IL-15 confidence and competition.

    A: IL-15 program data competitive with systemic treatments.